Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide disposition in an anephric child.

Jeannine S McCune1, Denise Adams, Alan C Homans

  • 1Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA. jmccune@u.washington.edu

Pediatric Blood & Cancer
|September 13, 2005
PubMed
Summary

Cyclophosphamide is eliminated in anephric children, with hemodialysis influencing its clearance and metabolite levels. Further research is needed to understand cyclophosphamide pharmacokinetics in this patient population.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Health-Related Quality of Life and Symptom Severity Among Patients With PIK3CA-Related Overgrowth Spectrum: A Mixed-Methods Study to Understand Real-World Experience With Alpelisib Treatment.

Pediatric blood & cancer·2026
Same author

Hybrid Systems Modeling of Donor T-Cell Responses and Graft-Versus-Host-Disease After Posttransplantation Cyclophosphamide Administration.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Neuro-oncology pediatrics·2026
Same author

Somatic Genetic Testing Provides Diagnosis of Verrucous Venous Malformation in an Individual with Discrepant Radiology, Pathology, and Clinical Findings.

Journal of vascular anomalies·2026
Same author

Impact of anticoagulation on quality of life in patients with slow-flow vascular malformations.

Blood vessels, thrombosis & hemostasis·2025

Area of Science:

  • Pharmacology
  • Nephrology
  • Pediatric Oncology

Background:

  • Limited data exist on cyclophosphamide pharmacokinetics in renal insufficiency, with no reports in anephric patients.
  • Cyclophosphamide is a critical chemotherapeutic agent used in treating various cancers, including Wilms tumor.

Observation:

  • This study characterized cyclophosphamide pharmacokinetics in a single anephric child with bilateral Wilms tumor, comparing data on and off hemodialysis.
  • Cyclophosphamide clearance was observed both on and off hemodialysis, indicating elimination in anephric patients.

Findings:

  • Median cyclophosphamide clearance was 5.34 L/hr*m(2) on hemodialysis and 3.82 L/hr*m(2) off hemodialysis.
  • Hydroxycyclophosphamide (HCY) AUC was higher on hemodialysis (20.6 microM*hr) compared to off hemodialysis (8.77 microM*hr).

Related Experiment Videos

  • Carboxyethylphosphoramide mustard (CEPM) AUC was similar to normal renal function controls when on hemodialysis (194 microM*hr) but elevated when off hemodialysis (383 microM*hr).

    • Implications:

    • Findings suggest cyclophosphamide is eliminated in anephric children, with hemodialysis impacting its disposition.
    • Elevated CEPM AUC off hemodialysis may have clinical significance, as CEPM levels correlate with patient outcomes.
    • Further pharmacokinetic studies of cyclophosphamide and its metabolites in anephric children are warranted for optimized treatment strategies.